Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1E)-2-nitro-1H-indene-1,3(2H)-dione oxime
-
-
(1Z)-2-nitro-1H-indene-1,3(2H)-dione oxime
-
-
(2E)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-(2-thienylcarbonyl)acrylonitrile
-
-
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
(2Z)-2-[(2E)-[(naphthalen-1-yl)methylidene]hydrazinylidene]-3-(2-phenoxyethyl)-1,3-thiazolidin-4-one
-
56.4% inhibition at 0.1 mM
(3aR,5R,6R,7R,7aR)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-3a-(aminomethyl)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2,3a-dimethyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3aR,5R,6S,7R,7aR)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(3E)-1-methyl-3-([[3-(trifluoromethyl)phenyl]amino]methylene)-1H-thieno[3,2-c][1,2]thiazin-4(3H)-one 2,2-dioxide
-
-
(3R,4R,5R,6S),N-(4,5,6-trihydroxyazepan-3-yl)-acetamide
-
68% inhibition at 1 mM
(3R,4R,5R,6S)-N-(4,5,6-trihydroxy-azepan-3-yl)-acetamide
-
93% inhibition at 1 mM
(3R,4S,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6R,7R),N-(4,5,6-trihydroxy-7-hydroxymethyl-azepan-3-yl)-acetamide
(3S,4R,5R,6R,7S),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
(3S,4R,5R,6S),N-(4,5,6-trihydroxyazepan-3-yl)-acetamide
-
99% inhibition at 1 mM
(5R,6R,7R)-5-(hydroxymethyl)-2-methyl-6,7-dihydro-5H-pyrano[3,2-d][1,3]thiazole-6,7-diol
-
-
(N-acetyl-D-glucosamine)2
non-competitive
(N-acetyl-D-glucosamine)3-6
competitive inhibition
(Z)-2-(((E)-benzylidene)hydrazono)-3-((benzyloxy)methyl)thiazolidin-4-one
-
62.7% inhibition at 0.01 mM; 62.7% inhibition at 0.1 mM
(Z)-2-(((E)-benzylidene)hydrazono)-3-(2-phenoxyethyl)thiazolidin-4-one
-
79.4% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(2-phenoxyethyl) thiazolidin-4-one
-
56.4% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(2-phenoxyethyl)thiazolidin-4-one
-
35.5% inhibition at 0.01 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(prop-2-yn-1-yl) thiazolidin-4-one
-
8.8% inhibition at 0.1 mM
(Z)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)-3-(prop-2-yn-1-yl)thiazolidin-4-one
-
8.8% inhibition at 0.1 mM
(Z)-3-((2-chlorothiazol-5-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
39% inhibition at 0.1 mM
(Z)-3-((2-chlorothiazol-5-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
39% inhibition at 0.1 mM
(Z)-3-((3,5-dimethylisoxazol-4-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
34.5% inhibition at 0.1 mM
(Z)-3-((3,5-dimethylisoxazol-4-yl)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
34.5% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-(4-bromo naphthalen-1-yl)methylene)hydrazono) thiazolidin-4-one
-
43.7% inhibition at 0.01 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-(4-bromonaphthalen-1-yl)methylene)hydrazono)thiazolidin-4-one
-
43.7% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-4-(dimethylamino)benzylidene)hydrazono)thiazolidin-4-one
-
63.5% inhibition at 0.01 mM; 63.5% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono) thiazolidin-4-one
-
85.9% inhibition at 0.1 mM, 35.5% inhibition at 0.01 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
85.9% inhibition at 0.1 mM
(Z)-3-((benzyloxy)methyl)-2-(((E)-naphthalen-2-ylmethylene)hydrazono)thiazolidin-4-one
-
59.8% inhibition at 0.01 mM; 59.8% inhibition at 0.1 mM
(Z)-3-(4-chlorobenzyl)-2-(((E)-naphthalen-1-yl methylene)hydrazono)thiazolidin-4-one
-
53.2% inhibition at 0.1 mM
(Z)-3-(4-fluorobenzyl)-2-(((E)-naphthalen-1-yl methylene)hydrazono)thiazolidin-4-one
-
41.7% inhibition at 0.1 mM
(Z)-3-(cyclobutylmethyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
9.0% inhibition at 0.1 mM
(Z)-3-(cyclopropylmethyl)-2-(((E)-naphthalen-1-ylmethylene)hydrazono)thiazolidin-4-one
-
1.0% inhibition at 0.1 mM
(Z)-3-allyl-2-(((E)-naphthalen-1-ylmethylene) hydrazono)thiazolidin-4-one
-
21.9% inhibition at 0.1 mM
(Z)-3-ethyl-2-(((E)-naphthalen-1-ylmethylene) hydrazono)thiazolidin-4-one
-
28.1% inhibition at 0.1 mM
1,1'-(1,3-dioxo-2-phenylpropane-1,3-diyl)bis(2,3-dihydro-1H-indole)
-
-
1,10-phenanthroline
-
concentration of 1 mM causes 25% inhibition
1,2,3-tris-[1-(2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-1H-1,2,3-triazol-4-yl)-2-ethyloxy]benzene
-
1,2-dideoxy-2'-butyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-ethyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-isobutyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-isopropyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor. About 17000fold more tightly than GlcNAc
1,2-dideoxy-2'-pentyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,2-dideoxy-2'-propyl-alpha-D-glucopyranoso-[2,1-d]-DELTA2'-thiazoline
-
-
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(1-adamantyl)ureido]-beta-D-glucopyranose
-
0.1 mM
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(2-allyl)thioureido]-beta-D-glucopyranose
-
0.1 mM
1,3,4,6-tetra-O-acetyl-2-deoxy-2-[3-(2-cyclohexyl)ureido]-beta-D-glucopyranose
-
0.1 mM
1,3-bis[3-(1-deoxy-D-glucit-1-yl)ureido]-4-methylbenzene
-
0.1 mM
1,6-bis[3-(1,3,4,6-tetra-O-acetyl-2-deoxy-beta-D-glucopyranos-2-yl)ureido]hexane
-
0.1 mM
1,6-bis{1-[3-(1-deoxy-D-glucit-1-yl)]ureido}hexane
-
0.1 mM
1,8-bis[3-(1,3,4,6-tetra-O-acetyl-2-deoxy-beta-D-glucopyranos-2-yl)ureido]octane
-
0.1 mM
1,9-bis-[3-(2-hydroxyethoxy)ethylthioureido]-nonane
-
0.1 mM
1,9-bis{1-[3-(1-deoxy-D-glucit-1-yl)]thioureido}nonane
-
0.1 mM
1-acetamido-2-deoxy-D-glucono-1,5-lactone
-
-
1-deoxy-1-(3-adamantylthioureido)-D-glucitol
-
0.1 mM
1-deoxy-1-(3-cyclohexylureido)-D-glucitol
-
0.1 mM
1-deoxy-1-[3-(1-adamantyl)ureido]-D-glucitol
-
0.1 mM
1-[2-(1H-benzimidazol-2-yl)phenyl]-3-[4-(benzyloxy)phenyl]urea
-
-
1-[5-acetyl-2-[4-(ethoxycarbonyl)piperidin-1-yl]phenyl]-1-methyldiazenium
-
-
2,2''-[azanediyldi(ethane-2,1-diyl)]di(1H-benzo[de]isoquinoline-1,3(2H)-dione)
-
M-31850
2,2'-(iminodiethane-2,1-diyl)bis(1H-benzo[de]isoquinoline-1,3(2H)-dione)
-
-
2-(2-([(4-methoxyphenyl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-([(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-hydroxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(2-pyridin-2-ylethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-(4-chlorobenzyl)-5-methyl-2,6-dihydro-1H-pyrrolo[3,4-d]pyridazin-1-one
-
-
2-(tetrahydrofuran-2-ylmethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
-
2-acetamido-1,2-deoxynojirimycin
-
2-acetamido-1,2-dideoxy-1,5-imino-D-glucitol
-
competitive inhibitor
2-acetamido-1,2-dideoxynojirimycin
2-acetamido-2-deoxy-D-fucono(1-4)lactone
-
-
2-acetamido-2-deoxy-D-galactono(1-4)lactone
2-acetamido-2-deoxy-D-galactonolactone
-
-
2-acetamido-2-deoxy-D-galactose
-
-
2-acetamido-2-deoxy-D-glucose
-
-
2-acetamido-2-deoxy-D-mannono-1,4-lactone
-
-
2-acetamido-2-deoxy-L-arabinono(1-4)lactone
-
-
2-acetamido-2-deoxy-N-([4-[(2,4-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2,6-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-alpha-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(2-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(3-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(4-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-([4-[(4-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
6.9% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
2-acetamido-2-deoxy-N-[(4-[[2-(trifluoromethyl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-beta-D-glucopyranosylamine
2-acetamido-2-deoxyglucono-1,4-lactone
2-acetamido-6-azido-2,6-dideoxy-D-galactono(1-4)lactone
-
-
2-acetamido-N-([4-[(2-amino-3-methylbenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(2-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
5.1% inhibition at 0.1 mM
2-acetamido-N-([4-[(2-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(3-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(3-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-([4-[(4-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
13.5% inhibition at 0.1 mM
2-acetamido-N-([4-[(4-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[([1,1'-biphenyl]-2-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
-
28.5% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-3-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[([1,1'-biphenyl]-4-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-acetamido-N-[(4-[[4-chloro-2-(propan-2-yl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
2-amino-1H-benzo[de]isoquinoline-1,3(2H)-dione
28.1% inhibition at 0.1 mM
2-amino-4-ethyl-5-(4-(trifluoromethyl)phenyl)pyrimidine
-
-
2-amino-4-ethyl-5-(4-chlorophenyl)pyrimidine
-
-
2-amino-6-(methoxymethyl)pyrimidin-4-ol
-
-
2-amino-6-ethyl-5-(4-chlorophenyl)pyrimidin-4(3H)-one
-
-
2-deoxy-2-(trimethylammonio)-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-D-glucopyranose
2-deoxy-2-acetamido-D-glucono(1-5)lactone
2-hydroxy-3-phenyl-4H-pyrimido[2,1-b][1,3]benzothiazol-4-one
-
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-(81-[5-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)pentyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
2-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethyl]-1H-benzo[de]isoquinoline-isoquinoline-1,3(2H)-dione
-
-
2-[2-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[2-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[3-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]propyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[(2-acetamido-beta-D-glucopyranosyl)thio]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[4-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexylamino]butyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
-
2-[[1-[(2-acetamido-beta-D-glucopyranosylthiomethyl)-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
17.9% inhibition at 0.1 mM
2-[[1-[2-[(2-acetamido-beta-D-glucopyranosyl)thio]ethyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
84% inhibition at 0.1 mM
2-[[1-[3-[(2-acetamido-beta-D-glucopyranosyl)thio]propyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
81.6% inhibition at 0.1 mM
2-[[1-[4-[(2-acetamido-beta-D-glucopyranosyl)thio]butyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
89.9% inhibition at 0.1 mM
2-[[1-[5-[(2-acetamido-beta-D-glucopyranosyl)thio]pentyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
91.9% inhibition at 0.1 mM
2-[[1-[6-[(2-acetamido-beta-D-glucopyranosyl)thio]hexyl]-1H-1,2,3-triazol-4-yl]methyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
93.2% inhibition at 0.1 mM
3,5-bis(4-fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
-
3-methoxy-1-(3,4,5-trimethoxyphenyl)-9,10-dihydrophenanthrene-2-carbonitrile
-
-
3-[2-(benzyloxy)-5-fluorophenyl]-5-(4-tert-butylphenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole
-
-
4,5-dihydronaphtho[1,2-b]thiophene-2-carbohydrazide
-
-
4-ethyl-5-[4-(trifluoromethyl)phenyl]pyrimidine
-
-
4-hydroxy-3-(methylthio)-N'-[(1E)-2-thienylmethylene]-4,5,6,7-tetrahydro-2-benzothiophene-1-carbohydrazide
-
-
4-nitrophenyl 2-acetamido-2-deoxy-beta-D-galactopyranoside
-
substrate inhibition, competitive
4-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucopyranoside
-
substrate inhibition, noncompetitive
4-[(E)-2-phenylvinyl]benzaldehyde O-(anilinocarbonyl)oxime
-
-
4-[4-(phenylethynyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]butanamide
-
-
5-(3,5-dimethylphenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(3-nitrophenyl)-2-furaldehyde N-(3-fluorophenyl)thiosemicarbazone
-
-
5-(4-chloro-1-methyl-1H-pyrazol-3-yl)-4,5-dihydro-1,3,4-thiadiazole-2-thiol
-
-
5-(4-chlorophenyl)-6-butylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-isopropylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-methylpyrimidine-2,4-diamine
-
-
5-(4-chlorophenyl)-6-propylpyrimidine-2,4-diamine
-
-
6-(aminomethyl)-5-(4-chlorophenyl)pyrimidine-2,4-diamine
-
-
6-(dimethylamino)-2-(2-([(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
-
95.9% inhibition at 0.1 mM
6-ethyl-5-(4-(trifluoromethyl)phenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(4-methoxyphenyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(m-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(o-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-(p-tolyl)pyrimidine-2,4-diamine
-
-
6-ethyl-5-phenylpyrimidine-2,4-diamine
-
-
7-diazonaphthalene-1,3-disulfonic acid
-
extract: 45% of activity remains
allyl ((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyrano-syl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)carbamate
antibodies
-
inhibit about 90% of in vitro activity
-
ascorbate
-
only in presence of Cu2+
beta-D-GalNAc-(1->4)beta-D-GlcNAc
-
beta-mercaptoethanol
-
with 2 mM hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 22%, hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside to 20%
chitobiose
-
concentration of 10 mM causes 25% inhibition
Chloramine T
-
0.1 mM, complete inhibition
conduritol beta-epoxide
-
CuCl2
-
5 mM, 37% inhibition
D-fructose
-
3 mM, 26% inhibition
diethyl dicarbonate
-
with 30 mM 1.1% of activity remains
dioxane
-
reversible inactivation, mixed-type inhibition, half-maximal inhibition at 0.68%
dithioerythritol
-
concentration of 2.5 mM decreases activity of the 3 enzyme forms in colonic mucosa by 20% at pH 4.2 and by 25% at pH 7.0, similar results with the 2 forms from colon tumors
dsRNA
mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion. Knockdown of transcripts results in phenotypes similar to those of NAG1 dsRNA-treated insects, but the effects are somewhat variable and less severe; mediates transcript depletion, NAG1 dsRNA is most effective in interrupting all three types of molts: larval-larval, larval-pupal, and pupal-adult, treated insects die after failing to completely shed their old cuticles
-
E-64
about 70% residual activity at 1 mM
erythritol
-
64.4% relative inhibition, three concentrations of 10, 50, and 100 mM tested
ethyl 3-(N-[[(4-chlorophenyl)amino]carbonyl]-S-methylsulfinimidoyl)-6,7-dihydro-2-benzothiophene-1-carboxylate
-
-
ethyl 5-[[3-(trifluoromethyl)phenyl]amino]pyrazolo[1,5-a]quinazoline-3-carboxylate
-
-
fructose
-
concentration of 10 mM causes 38% inhibition
high ionic strength
-
above 0.1 no cleavage of GM2
-
K+
-
slight inhibition at 5 mM
KCl
with 1 mM 80% of activity remains, with 2 mM 50% of activity remains
leupeptin
about 90% residual activity at 1 mM
LOGNAc
i.e. 2-acetamido-2-deoxy-D-gluconhydroximo-1,5-lactone
methyl-alpha-D-mannoside
-
concentration of 10 mM causes 25% inhibition
MgCl2
-
1 mM, 13% inhibition
MgSO4
-
10 mM, 22% inhibition
MnCl2
-
1 mM, complete inhibition
Monoiodoacetic acid
-
with 1 mM 73% of activity remains
N,N,N,N-tetraacetylchitotetraose
N,N,N-triacetylchitotriose
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)picolinamide
N-((3S,4R,5S)-1-(7-(bis(4-methoxybenzyl)amino)heptyl)-4,5-dihydroxy-5-(hydroxymethyl)piperidin-3-yl)acetamide
-
-
N-((3S,4R,5S)-4,5-dihydroxy-5-(hydroxymethyl)-1-(7-(4-methoxybenzylamino)heptyl)piperidin-3-yl)acetamide
-
-
N-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
24.9% inhibition at 0.1 mM
N-(3,5-dichlorophenyl)-2-[[4-(3,4-dimethylthieno[2,3-b]thien-2-yl)pyrimidin-2-yl]thio]acetamide
-
-
N-(3R,4S,5R,6R,7S)-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
N-(7-((3S,4R,5S)-5-acetamido-3,4-dihydroxy-3-(hydroxymethyl)piperidin-1-yl)heptyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
-
-
N-acetyl-beta-D-galactosamine
N-acetyl-beta-D-galactosaminolactone
N-acetyl-beta-D-glucosamine
N-acetyl-beta-D-glucosaminolactone
N-acetylcastanospermine
30% with 1 mM inhibitor and 2.5 mM substrate
N-acetylgalactosamine
-
61.9% relative inhibition, three concentrations of 10, 50, and 100 mM tested
N-acetylglucosamine
-
76.2% relative inhibition, three concentrations of 10, 50, and 100 mM tested
N-acetylglucosamine thiazoline
-
-
N-acetylglucosamine(1-5)lactone
-
-
N-acetylglucosamine-6-sulfate
-
with 10 mM 86% of activity remains
N-acetylglucosamine-isothiocyanate
-
with 10 mM 46% of activity remains
N-Acetylimidazole
-
1 mM, 31% inhibition
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
N-butyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
-
N-butyldeoxynojirimycin
-
N-ethyl-5-phenyl-isoxazolium-3'-sulfonate
-
with 30 mM 23.3% of activity remains
N-[(1S,2R,5R,6R)-2-amino-5,6-dihydroxy-4-(hydroxymethyl)-cyclohex-3-en-1-yl]acetamide hydrochloride
N-[(3S,4R,5R,6S)-4,5,6-trihydroxyazepan-3-yl]acetamide
N-[1(7-amino-heptyl)]-2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
competitive inhibitor
N-[1(7-azido-heptyl)]-2-acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol
-
-
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-2-[(2-acetamido-beta-D-glucopyranosyl) thio]acetamide
18.4% inhibition at 0.1 mM
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
18.4% inhibition at 0.1 mM
N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
25.8% inhibition at 0.1 mM
N-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
29.2% inhibition at 0.1 mM
N-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
25.3% inhibition at 0.1 mM
N-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-2-[(2-acetamido-beta-D-glucopyranosyl)thio]acetamide
29.1% inhibition at 0.1 mM
N-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-3-[(2-acetamido-beta-D-glucopyranosyl)thio]propanamide
26.9% inhibition at 0.1 mM
N-[[1-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]-2-(2-acetamido-beta-D-glucopyranosylthio)acetamide
Na+
-
slight inhibition at 5 mM
Na2S2O3
-
9% inhibition at 1 mM
NaOH
-
unbroken bacteria: total inhibition with 1 M, extract: with 1 M 9% of activity remains
naphthalene-1,4-diyl bis(trifluoroacetate)
-
-
NH4+
-
20% inhibition with 2 M, 5% inhibition with 2 M
Ni2+
-
strong inhibition at 5 mM
O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate
-
PUGNAc
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate
O-(2-deoxy-2-butamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-hexamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-isobutamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-isovaleramido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-propamido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-deoxy-2-valeramido-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-2-acetamido-3-O-(D-carboxyethyl)-2-deoxy-D-glucose
-
substrate inhibition above 0.2 mM
p-aminophenyl 1-thio-beta-L-fucopyranoside
-
-
p-chloromercuriphenylsulfonate
p-hydroxymercuribenzoic acid
-
1 mM, 22% inhibition
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
p-nitrophenyl 2-deoxy-2-thioacetamido-beta-D-galactopyranoside
-
competitive inhibition
p-nitrophenyl 2-deoxy-2-thioacetamido-beta-D-glucopyranoside
-
competitive inhibition
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
p-thiophenyl-1-thio-N-acetyl-beta-D-glucosaminide
-
-
Pb(NO3)2
-
10 mM, 50% inhibition
phenyl N-acetylgalactosaminide
-
-
phenyl N-acetylglucosaminide
-
-
Phenylglyoxal
-
1 mM, 20% inhibition
phenylmethanesulfonyl fluoride
about 35% residual activity at 1 mM
RNAi
-
mediates mRNA suppression in S2 cells. About 50% reduction of Glc-NAcase activity through RNAi-mediated suppression regardless of applied dsRNA amounts compared to the case of original human erythropoietin-expressing S2 cells. GlcNAcase suppression decreases the amount of terminal Man available
-
S-(thiophen-3-ylmethyl) (2,2'-bithiophen-5-ylcarbonyl)thiocarbamate
-
-
SnCl2
-
10 mM, 44% inhibition
sodium taurodeoxycholate
-
-
sucrose
-
concentration of 10 mM causes 9% inhibition
tert-butyl {[(3aR,5R,6S,7R,7aR)-6,7-dihydroxy-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-3a-yl]methyl}carbamate
-
-
thimerosal
-
inhibits activity in mucosal and tumor enzymes, 50% of activity remains after 1 h if form A is treated with 0.20 mM, form B with 1.75 mM and form I with 0.65 mM
thiophenyl-N-acetyl-beta-D-glucosaminide
-
-
ZnSO4
-
1 mM, 77% inhibition
(3R,4S,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
99% inhibition at 1 mM
(3R,4S,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
98% inhibition at 1 mM
(3S,4R,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
93% inhibition at 1 mM
(3S,4R,5R,6R,7R),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
98% inhibition at 1 mM
(3S,4R,5R,6R,7R),N-(4,5,6-trihydroxy-7-hydroxymethyl-azepan-3-yl)-acetamide
-
74% inhibition at 1 mM
(3S,4R,5R,6R,7R),N-(4,5,6-trihydroxy-7-hydroxymethyl-azepan-3-yl)-acetamide
-
88% inhibition at 1 mM
(3S,4R,5R,6R,7S),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
99% inhibition at 1 mM
(3S,4R,5R,6R,7S),N-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
100% inhibition at 1 mM
2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
-
poor inhibitor
2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
-
poor inhibitor
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
-
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
noncompetitive inhibitor
2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
potent noncompetitive inhibitor
2-acetamido-1,2-dideoxynojirimycin
-
GlcNAcase suppression improves the N-glycan patterns in S2 cells
2-acetamido-1,2-dideoxynojirimycin
-
2-acetamido-2-deoxy-D-galactono(1-4)lactone
-
-
2-acetamido-2-deoxy-D-galactono(1-4)lactone
Helicella ericetorum
-
complete inhibition with 100 mM
2-acetamido-2-deoxy-D-galactono(1-4)lactone
-
-
2-acetamido-2-deoxy-D-galactono(1-4)lactone
-
with 10 mM 75% inhibition
2-acetamido-2-deoxy-N-([4-[(2,4-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
7.0% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2,4-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
54.5% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2,6-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
2.7% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2,6-dichlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
23.5% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
2.4% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
19.9% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
0.9% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
19.3% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-alpha-D-glucopyranosylamine
-
19.5% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-alpha-D-glucopyranosylamine
32% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
13.9% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(2-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
21% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
3.3% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
19.8% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
3.1% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-hydroxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
17.6% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
18.2% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-methoxybenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
17.4% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
10.2% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(3-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
24.5% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
8.0% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-fluorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
24.3% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
-
16.2% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-([4-[(4-nitrobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-beta-D-glucopyranosylamine
17.8% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-[(4-[[2-(trifluoromethyl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-beta-D-glucopyranosylamine
-
11.1% inhibition at 0.1 mM
2-acetamido-2-deoxy-N-[(4-[[2-(trifluoromethyl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-beta-D-glucopyranosylamine
22.6% inhibition at 0.1 mM
2-acetamido-2-deoxyglucono-1,4-lactone
-
-
2-acetamido-2-deoxyglucono-1,4-lactone
-
-
2-acetamido-N-([4-[(2-amino-3-methylbenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
17.8% inhibition at 0.1 mM
2-acetamido-N-([4-[(2-amino-3-methylbenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
13.6% inhibition at 0.1 mM
2-acetamido-N-([4-[(2-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
3.8% inhibition at 0.1 mM
2-acetamido-N-([4-[(2-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
9.8% inhibition at 0.1 mM
2-acetamido-N-([4-[(3-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
10.9% inhibition at 0.1 mM
2-acetamido-N-([4-[(3-aminobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
16.6% inhibition at 0.1 mM
2-acetamido-N-([4-[(3-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
13.8% inhibition at 0.1 mM
2-acetamido-N-([4-[(3-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
15.7% inhibition at 0.1 mM
2-acetamido-N-([4-[(4-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
-
23% inhibition at 0.1 mM
2-acetamido-N-([4-[(4-chlorobenzamido)methyl]-1H-1,2,3-triazol-1-yl]acetyl)-2-deoxy-beta-D-glucopyranosylamine
23.4% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-3-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
-
6.6% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-3-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
44.1% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-4-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
-
26.2% inhibition at 0.1 mM
2-acetamido-N-[(4-[[([1,1'-biphenyl]-4-carbonyl)amino]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
17.6% inhibition at 0.1 mM
2-acetamido-N-[(4-[[4-chloro-2-(propan-2-yl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
-
9.2% inhibition at 0.1 mM
2-acetamido-N-[(4-[[4-chloro-2-(propan-2-yl)benzamido]methyl]-1H-1,2,3-triazol-1-yl)acetyl]-2-deoxy-beta-D-glucopyranosylamine
31.1% inhibition at 0.1 mM
2-deoxy-2-(trimethylammonio)-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-D-glucopyranose
-
natural selective inhibitor, contains 3 GlcNAc residues
2-deoxy-2-(trimethylammonio)-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-D-glucopyranose
natural selective inhibitor, contains 3 GlcNAc residues
2-deoxy-2-acetamido-D-glucono(1-5)lactone
-
-
2-deoxy-2-acetamido-D-glucono(1-5)lactone
-
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
-
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
-
-
2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-D-glucopyranose
-
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-(81-[5-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)pentyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
-
49.1% inhibition at 0.1 mM
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-(81-[5-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)pentyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
82.8% inhibition at 0.1 mM
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
-
48.7% inhibition at 0.1 mM
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
83.6% inhibition at 0.1 mM
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
-
42.9% inhibition at 0.1 mM
2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)thio]-N-([1-[4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl]-1H-1,2,3-triazol-4-yl]methyl)acetamide
86.2% inhibition at 0.1 mM
acetamide
-
with 10 mM 70% of activity remains
acetamide
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside
acetate
-
with 50 mM 45% of activity remains
acetate
-
inhibits N-acetylhexosaminidase
acetate
-
with 30 mM 39.8% of liver enzyme type S, 71.4% of brain enzyme type S, 33.3-39.4% of liver enzyme type A and 30.6-38.2% of liver enzyme type B remains
acetate
-
with 0.02 M 49% of activity remains
acetate
-
80% inhibition with 66 mM
acetate
-
highest activity in phosphaute buffer and McIlvaine buffer. Activity in K-acetate buffer and K-acetate buffer is reduced to about 60%
acetate
-
inhibits N-acetylhexosaminidase
acetate
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside
acetate
-
concentration of 1 mM causes 30% inhibition
Ag+
-
10 mM, 30% loss of activity
Ag+
-
0.01 mM cause 30% inhibition, 2 mM cause 100% inhibition
Ag+
-
inhibits N-acetylhexosaminidase, -galactosaminidase and -glucosaminidase
Ag+
-
complete inactivation with 0.1 mM
Ag+
-
0.25 mM, significant inhibition
Ag+
-
minor isozyme: 2% of activity remains with 5 mM, major isozyme: 38% of activity remains with 2 mM
Ag+
-
with 0.1 mM 63% of activity remains
Ag+
-
enzyme incubated before addition of substrate: with 0.0025 mM 18% of activity remains
Ag+
-
concentration of 2 mM causes 70.9% inhibition
Ag+
-
1 and 2 mM cause 70 and 92% inhibition respectively
Ag+
-
inhibits N-acetylhexosaminidase, -galactosaminidase and -glucosaminidase
Ag+
-
completely inactivates all 3 enzyme forms in colonic mucosa
Ag+
25% residual activity at 1 mM
Ag+
-
with 7 mM 5% of activity remains
Ag+
-
with 1 mM 43% of N-acetylgalactosaminidase and 59% of N-acetylglucosaminidase activity remains
Ag+
-
1 mM, about 50% inhibition
AgNO3
-
0.1 mM, complete inhibition
AgNO3
-
1 mM final concentration
AgNO3
-
5 mM, 93% inhibition
AlCl3
-
10 mM, 20% inhibition
AlCl3
-
1 mM, 24% inhibition
allyl ((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyrano-syl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)carbamate
-
16.4% inhibition at 0.1 mM
allyl ((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyrano-syl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)carbamate
25.7% inhibition at 0.1 mM
Ba2+
-
10 mM, 30% loss of activity
Ba2+
-
with 10 mM 85% of activity remains
Ca2+
-
100 mM
Ca2+
-
1 M and more cause 100% inhibition
Ca2+
-
with 0.03 mM 42.9% of activity remains
Ca2+
-
1 mM, 16% inhibition of isoenzyme II, slight activation of isoenzyme I
Ca2+
37% inhibition at 1 mM, 73% at 50 mM
Ca2+
about 80% residual activity at 1 mM
Ca2+
-
slight inhibition at 5 mM
Ca2+
92% residual activity at 1 mM
CaCl2
-
1 mM, 13% inhibition
CaCl2
-
1 mM, 30% inhibition
Cd2+
-
with 2 mM hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 41%, hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside to 38%
Cd2+
-
2 mM cause 41% inhibition, 10 mM cause 59% inhibition
Cd2+
about 85% residual activity at 1 mM
Cd2+
about 85% residual activity at 10 mM
Cd2+
-
14%, 20% and 67% inhibition with 0.01 mM, 2 mM and 10 mM
Co2+
-
10 mM cause 37% inhibition
Co2+
about 90% residual activity at 1 mM
CoCl2
-
1 mM, 15% inhibition
CoCl2
-
1 mM, complete inhibition
Cu2+
-
about 70% inhibition of isoform Am2301 at 2 mM, about 30% inhibition of isoform Am2446 at 2 mM
Cu2+
-
with 10 mM 78% of activity remains
Cu2+
-
1 mM, 91% inhibition of isoenzyme I, 22% inhibition of isoenzyme II
Cu2+
-
0.5 mM, significant inhibition
Cu2+
-
minor isozyme: 19% of activity remains with 10 mM, major isozyme: 47% of activity remains with 10 mM
Cu2+
-
with 10 mM 47% of activity remains
Cu2+
-
only in presence of ascorbate
Cu2+
complete inhibition at 1-50 mM
Cu2+
about 80% residual activity at 1 mM
Cu2+
-
strong inhibition at 5 mM
Cu2+
about 87% residual activity at 10 mM
Cu2+
-
isoenzyme I; isoenzyme II
Cu2+
94% residual activity at 1 mM
Cu2+
-
1 mM, about 50% inhibition
CuSO4
-
10 mM, 75% inhibition
CuSO4
-
1 mM, 36% inhibition
CuSO4
-
1-10 mM final concentration
D-mannose
-
concentration of 10 mM causes 33% inhibition
D-mannose
Helicella ericetorum
-
75% inhibition with 100 mM
D-mannose
-
3 mM, 19% inhibition
D-mannose
-
with 10 mM 30% inhibition
EDTA
-
about 40% inhibition of isoform Am2301 at 2 mM, isoform Am2446 is not inhibited by EDTA
EDTA
-
with 50 mM 54% inhibition
EDTA
91% residual activity at 1 mM
EDTA
-
concentration of 1 mM causes 40% inhibition
Fe2+
-
-
Fe2+
-
with 0.2 mM 28% of activity remains, citrate buffer, not inhibitory in succinate or acetate buffer
Fe2+
-
concentration of 2 mM causes 7.8% inhibition
Fe2+
about 30% residual activity at 1 mM
Fe2+
-
2 mM causes 30-35% loss of activity of beta-NAHA-IA, 10 mM causes 30-35% loss of activity of beta-NAHA-IB
Fe2+
-
1 mM reduces activity by 59%
Fe2+
72% residual activity at 1 mM
Fe2+
-
with 7 mM 16% of activity remains
Fe2+
-
both hexosaminidase activities of forms II, III and IV inhibited
Fe3+
-
about 60% inhibition of isoform Am2446 at 2 mM, about 15% inhibition of isoform Am2301 at 2 mM
Fe3+
-
with 10 mM 5% of activity remains
Fe3+
Helicella ericetorum
-
concentration of 10 mM results in 85% inhibition
Fe3+
65% inhibition at 1 mM, complete at 50 mM
Fe3+
-
concentration of 2 mM causes 53.1% inhibition
Fe3+
about 55% residual activity at 1 mM
Fe3+
-
concentration of 10 mM reduces activity by 23%
Fe3+
-
glucosaminidase-activity of forms II, III and IV are depressed, galactosaminidase-activity of forms III and IV are inhibited
Fe3+
-
concentration of 1 mM causes 70-80% inhibition
FeCl3
-
1 mM, complete inhibition
FeCl3
-
5 mM, 90% inhibition
fucoidan
-
0.025 mg/ml, 19% inhibition
fucoidan
-
88% inhibition at 3 mM
galactosamine
-
inhibits N-acetylhexosaminidase
galactosamine
-
competitive inhibitor, less potent than glucosamine
galactosamine
-
with 30 mM 84.3-89.3% of liver enzyme type A and 79.6-87.8% of liver enzyme type B remains
galactosamine
-
inhibits N-acetylhexosaminidase
galactosamine
-
with 10 mM 84.0% of activity remains
galactose
-
concentration of 10 mM causes 15% inhibition
GlcNAc
-
exochitinase
glucosamine
-
inhibits N-acetylhexosaminidase
glucosamine
-
competitive inhibitor, more potent than galactosamine
glucosamine
-
with 30 mM 72.2-76.3% of liver enzyme type A and 65.7-73.3% of liver enzyme type B remains
glucosamine
-
1 mM, 22% inhibition
glucosamine
-
inhibits N-acetylhexosaminidase
glucosamine
-
with 10 mM 29.3% of activity remains
glucose
-
concentration of 10 mM causes 30% inhibition
glucose
-
1 mM, 35% inhibition
Hg2+
-
with 2 mM hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 24%, hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside to 20%
Hg2+
-
10 mM, 33% loss of activity
Hg2+
-
0.01 mM, 19% inhibition, 2 mM cause 97% inhibition
Hg2+
-
Ex 1, Ex 2 and alimentary canal enzyme
Hg2+
-
with 0.03 mM 7.1% of activity remains
Hg2+
-
complete inactivation with 0.1 mM
Hg2+
-
1 mM, 97% inhibition of isoenzyme I, 95% inhibition of isoenzyme II
Hg2+
-
0.25 mM, significant inhibition
Hg2+
-
minor isozyme: 5% of activity remains with 0.01 mM, major isozyme: 53% of activity remains with 0.01 mM
Hg2+
-
concentration of 0.1 mM results in total loss of activity
Hg2+
Helicella ericetorum
-
concentration of 10 mM results in 97% inhibition
Hg2+
-
with 0.75 M 6% of activity remains
Hg2+
-
added with substrate: with 0.0025 mM 45% of activity remains, enzyme incubated before addition of substrate: with 0.0025 mM 25% of activity remains
Hg2+
-
concentration of 2 mM causes 98.9% inhibition
Hg2+
-
low molecular weight form EII, at 0.25 mM
Hg2+
-
0.05 and 0.1 mM cause 45 and 70% inhibition
Hg2+
-
strong inhibition at 5 mM
Hg2+
-
concentration of 10 mM causes 39% inhibition
Hg2+
-
0.05 mM results in significant inhibition
Hg2+
-
all 4 isozymes, at 1 mM
Hg2+
-
1 mM reduces activity by 89%
Hg2+
-
completely inactivates all 3 enzyme forms in colonic mucosa
Hg2+
-
with 1 mM 13% of activity remains
Hg2+
-
isoenzyme I; isoenzyme II
Hg2+
5% residual activity at 1 mM
Hg2+
-
concentration of 7 mM results in total loss of activity
Hg2+
-
slight inhibition at 10 mM
Hg2+
-
37% inhibition with 0.01 mM, complete inhibition with 2 mM
Hg2+
-
with 1 mM 84% of N-acetylgalactosaminidase and 90% of N-acetylglucosaminidase activity remains
Hg2+
-
1 mM, about 50% inhibition
Hg2+
-
concentration of 1 mM causes complete inhibition
Hg2+
with 1 mM 50% of activity remains, with 5 mM 10% of activity remains
HgCl2
-
0.1 mM, complete inhibition
HgCl2
-
1 mM, complete inhibition
HgCl2
-
70% inhibition at 1 mM
HgCl2
-
1 mM final concentration
HgCl2
-
5 mM, 96% inhibition
iodoacetamide
-
-
iodoacetamide
-
1 mM, 16% inhibition
iodoacetamide
-
1 mM, 16% inhibition
lactose
-
lactose
-
concentration of 10 mM causes 25% inhibition
lactose
-
3 mM, 20% inhibition
maltose
-
3 mM, 33% inhibition
mannosamine
-
-
mannosamine
-
with 10 mM 80% inhibition
Mg2+
-
10 mM, 9% loss of activity
Mg2+
-
0.5 M causes 78% inhibition, 1 M causes 82% inhibition, 2 M and more cause 100% inhibition
Mg2+
-
with 0.03 mM 71.4% of activity remains
Mg2+
-
with 10 mM 85% of activity remains
Mg2+
-
1 mM, 33% inhibition of isoenzyme II, slight activation of isoenzyme I
Mg2+
slightly inhibitory at 1-50 mM
Mg2+
about 85% residual activity at 1 mM
Mg2+
-
slight inhibition at 5 mM
Mn2+
-
10 mM, 31% loss of activity
Mn2+
-
with 10 mM 82% of activity remains
Mn2+
85% inhibition at 1-50 mM
Mn2+
about 85% residual activity at 1 mM
N,N,N,N-tetraacetylchitotetraose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
N,N,N,N-tetraacetylchitotetraose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside; with 1 mM 45% of N-glucosaminidase- but only 16% of N-galactosaminidase-activity remains
N,N,N-triacetylchitotriose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
N,N,N-triacetylchitotriose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside; with 1 mM 45% of N-glucosaminidase- but only 19% of N-galactosaminidase-activity remains
N,N-diacetylchitobiose
-
-
N,N-diacetylchitobiose
-
with 0.1 mM 81% and with 2 mM 32% of activity remains
N,N-diacetylchitobiose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
N,N-diacetylchitobiose
-
inhibits hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside stronger than hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside; with 1 mM 54% of N-glucosaminidase- but only 23% of N-galactosaminidase-activity remains
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide
-
13.1% inhibition at 0.1 mM
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide
29.2% inhibition at 0.1 mM
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)picolinamide
-
6.6% inhibition at 0.1 mM
N-((1-(2-((2-acetamido-2-deoxy-beta-D-glucopyranosyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)picolinamide
22.6% inhibition at 0.1 mM
N-(3R,4S,5R,6R,7S)-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
40% inhibition at 1 mM
N-(3R,4S,5R,6R,7S)-(3,5,6-trihydroxy-7-hydroxymethyl-azepan-4-yl)-acetamide
-
91% inhibition at 1 mM
N-acetyl-beta-D-galactosamine
-
competitive
N-acetyl-beta-D-galactosamine
-
-
N-acetyl-beta-D-galactosaminolactone
-
-
N-acetyl-beta-D-galactosaminolactone
-
-
N-acetyl-beta-D-glucosamine
inhibited by GlcNAc, but not by GalNAc
N-acetyl-beta-D-glucosamine
-
-
N-acetyl-beta-D-glucosaminolactone
-
with 0.02 30% of activity remains
N-acetyl-beta-D-glucosaminolactone
-
-
N-acetyl-beta-D-glucosaminolactone
-
with 0.002 mM 65% of activity remains
N-acetyl-beta-D-glucosaminolactone
Helicella ericetorum
-
complete inhibition with 100 mM
N-acetyl-beta-D-glucosaminolactone
-
untreated: with 0.02 mM 65% of activity remains, treated with 7-diazonaphtalene-1,3-disulfonic acid: with 0.02 mM 70% of activity remains
N-acetyl-beta-D-glucosaminolactone
-
-
N-acetyl-beta-D-glucosaminolactone
-
-
N-acetyl-beta-D-glucosaminolactone
-
both isozymes
N-acetyl-beta-D-glucosaminolactone
Sclerotinia fructigena
-
-
N-acetyl-beta-D-glucosaminolactone
-
with 1 mM 4.7% of activity and with 0.1 mM 6.6% of activity remains
N-acetyl-beta-D-glucosaminolactone
-
with 10 mM 75% inhibition
N-acetyl-beta-D-glucosaminolactone
-
-
N-acetyl-D-galactosamine
-
with 10 mM the hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 26%
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
with 60 mM 45% of activity remains
N-acetyl-D-galactosamine
-
inhibits N-acetylhexosaminidase and -galactosaminidase
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
with 10 mM 20% of activity remains
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
concentration of 10 mM causes 28% inhibition
N-acetyl-D-galactosamine
-
competitive inhibitor; more potent than N-acetyl-D-glucosamine
N-acetyl-D-galactosamine
Helicella ericetorum
-
80% inhibition with 100 mM
N-acetyl-D-galactosamine
-
with 30 mM 12.1% activity of liver enzyme type S, 13.6% of brain enzyme type S, 3.2-8.6% of liver enzyme type A and 2.9-9.9% of liver enzyme type B remains
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
60% inhibition with 1 mM
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
45% inhibition at 20 mM
N-acetyl-D-galactosamine
-
inhibits N-galactosaminidase
N-acetyl-D-galactosamine
-
inhibits N-acetylhexosaminidase and -galactosaminidase
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
with 10 mM 52.6% of activity remains
N-acetyl-D-galactosamine
-
concentration of 10 mM causes 80% inhibition
N-acetyl-D-galactosamine
-
PI: concentration of 30 mM causes 69% inhibition, PII: concentration of 30 mM causes 80% inhibition
N-acetyl-D-galactosamine
-
-
N-acetyl-D-galactosamine
-
competitive inhibitor
N-acetyl-D-galactosamine
-
competitive inhibitor
N-acetyl-D-glucosamine
-
with 10 mM the hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside is reduced to 32%
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
with 60 mM 24% of activity remains
N-acetyl-D-glucosamine
-
inhibits N-acetylhexosaminidase and -glucosaminidase
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
with 10 mM 88% of activity remains
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
competitive inhibitor; concentration of 10 mM causes 80% inhibition
N-acetyl-D-glucosamine
-
competitive inhibitor; less potent than N-acetyl-D-galactosamine
N-acetyl-D-glucosamine
Helicella ericetorum
-
80% inhibition with 100 mM
N-acetyl-D-glucosamine
-
with 30 mM 40.7% activity of liver enzyme type S, 19.9% of brain enzyme type S, 19.9-24.6% of liver enzyme type A and 20.9-30.5% of liver enzyme type B remains
N-acetyl-D-glucosamine
-
with 0.75 M 34% of activity remains
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
with 2 mM 85%, with 4 mM 75%, with 8 mM 65% and with 12 mM 59% of activity remains
N-acetyl-D-glucosamine
-
inhibits N-glucosaminidase
N-acetyl-D-glucosamine
-
inhibits N-acetylhexosaminidase and -glucosaminidase
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
with 10 mM 64.2% of activity remains
N-acetyl-D-glucosamine
-
concentration of 10 mM causes 60% inhibition
N-acetyl-D-glucosamine
-
competitive inhibitor
N-acetyl-D-glucosamine
-
with 10 mM 33-35% of activity remains
N-acetyl-D-glucosamine
-
-
N-acetyl-D-glucosamine
-
inhibits N-acetylgalactosaminidase activity
N-acetyl-D-glucosamine
-
competitive inhibitor
N-acetyl-D-glucosamine
-
competitive inhibitor
N-acetylmannosamine
-
with 10 mM 83% of activity remains
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
-
potent inhibitor
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
-
competitive inhibitor
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-D-arabinitol
-
weak competitive inhibitor
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
-
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
noncompetitive inhibitor
N-benzyl-2-acetamido-1,2,4-trideoxy-1,4-imino-L-arabinitol
-
potent noncompetitive inhibitor, inhibits human placenta beta-N-acetylhexosaminidase 2.5fold better than DNJ-NAc 13
N-bromosuccinimide
-
with 0.025 mM 4.4% of activity remains
N-bromosuccinimide
-
modifcation of the indole group of tryptophan by N-bromosuccinimide completely inactivates the enzyme
N-bromosuccinimide
-
modifcation of the indole group of tryptophan by N-bromosuccinimide completely inactivates the enzyme
N-ethylmaleimide
-
N-acetylglucosaminidase
N-ethylmaleimide
-
N-acetylglucosaminidase
N-[(1S,2R,5R,6R)-2-amino-5,6-dihydroxy-4-(hydroxymethyl)-cyclohex-3-en-1-yl]acetamide hydrochloride
-
1-acetamido derivative of 6-epi-valienamine, route enabling synthesis described
N-[(1S,2R,5R,6R)-2-amino-5,6-dihydroxy-4-(hydroxymethyl)-cyclohex-3-en-1-yl]acetamide hydrochloride
-
1-acetamido derivative of 6-epi-valienamine, route enabling synthesis described
N-[(3S,4R,5R,6S)-4,5,6-trihydroxyazepan-3-yl]acetamide
-
-
N-[(3S,4R,5R,6S)-4,5,6-trihydroxyazepan-3-yl]acetamide
-
99% inhibition at 1 mM
N-[[1-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]-2-(2-acetamido-beta-D-glucopyranosylthio)acetamide
-
46.6% inhibition at 0.1 mM
N-[[1-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl]-1H-1,2,3-triazol-4-yl]methyl]-2-(2-acetamido-beta-D-glucopyranosylthio)acetamide
81.4% inhibition at 0.1 mM
NaCl
-
10 mM final concentration
NaCl
with 1 mM 80% of activity remains, with 2 mM 50% of activity remains
NAG-thiazoline
-
mechanism-based inhibitor
naphthalimide
-
-
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate
-
inhibitor of both human O-GlcNAcase and human beta-hexosaminidase
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate
60% inhibition with 1 mM inhibitor and 2.5 mM substrate
p-chloromercuribenzoate
-
0.1 mM cause 16% inhibition
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
form A: 93% inhibition with 0.1 mM, form P: 98% inhibition with 0.1 mM
p-chloromercuribenzoate
-
concentration of 2 mM causes 28.5% inhibition
p-chloromercuribenzoate
-
0.025 and 0.05 mM cause 70 and 83% inhibition
p-chloromercuribenzoate
-
with 1 mM 20% of activity remains
p-chloromercuribenzoate
-
43% inhibition with 0.5 mM
p-chloromercuribenzoate
-
inhibits forms II, III and IV, competitive inhibition
p-chloromercuriphenylsulfonate
-
with 1 mM 38.3% of liver enzyme type S, 14.2% of brain enzyme type S, 1.9-2.2% of liver enzyme type A and 2.6-9.9% of liver enzyme type B remains
p-chloromercuriphenylsulfonate
-
concentration of 10 mM inhibited activity by 46%
p-hydroxymercuribenzoate
-
inhibits N-acetylhexosaminidase, -galactosaminidase and -glucosaminidase
p-hydroxymercuribenzoate
-
inhibits N-acetylhexosaminidase, -galactosaminidase and -glucosaminidase
p-hydroxymercuribenzoate
-
forms A and I retain 50% of glucosaminidase-activity if treated with 0.005 mM at pH 4.2, 5.6 or 7.0 for 15 min, glucosaminidase-activity of form B is stable at pH 4.2 and 7.0 in presence of 0.005 mM and inactivated by less than 5% at pH 5.6, galactosaminidase-activity is decreased by 50% if form A and I was treated with 0.1 mM at pH 4.2, 5.6 or 7.0, galactosaminidase-activity of form B is stable
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
-
p-methoxyphenyl 2-trimethylammonium-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranosyl-(1,4)-2-acetamino-2-deoxy-beta-D-glucopyranoside
-
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
-
-
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
-
at higher concentrations
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
-
-
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
-
only beta-NAHA-IA, above 3.5 mM
p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside
Sclerotinia fructigena
-
inhibition by excess of substrate
PUGNAc
-
i.e. O-(2-acetamido-2-deoxy-D-glucopyranosylidenamino) N-phenylcarbamate, complete inhibition at 0.001 mM
PUGNAc
-
97.3% inhibition at 0.1 mM
PUGNAc
i.e. O-(2-acetamido-2-deoxy-D-glucopyranosylidenamino) N-phenylcarbamate, 97.5% inhibition at 0.1 mM
PUGNAc
-
i.e. O-(2-acetamido-2-deoxy-D-glucopyranosylidenamino) N-phenylcarbamate
PUGNAc
98.9% inhibition at 0.1 mM
PUGNAc
i.e. O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
pyrimethamine
-
-
pyrimethamine
-
i.e. 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
SDS
-
almost complete inhibition at 1.0-0.1% (v/v) SDS
SDS
-
21% inhibition at 1 mM
SDS
58% inhibition at 1% (w/v)
Sodium acetate
-
with 50 mM 27% inhibition
Sodium acetate
-
with 10 mM 50% of activity remains
Sodium acetate
Helicella ericetorum
-
concentration of 10 mM results in 20% inhibition
Sodium acetate
-
concentration of 60 mM causes 80% inhibition
Sodium acetate
-
inhibits only N-acetylglucosaminidase-activity, concentration of 10 mM causes 30% inhibition
TMG-chitotriomycin
-
-
TMG-chitotriomycin
mechanism of selective inhibition is related to the existence of the +1 subsite at the active pocket of OfHex1 and a key residue, Trp490, at this site. Mutation of Trp490 to Ala leads to a 2277fold decrease in sensitivity toward TMG-chitotriomycin as well as an 18-fold decrease in binding affinity for the substrate (GlcNAc)2
Urea
-
with 2 mM hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-glucopyranoside is reduced to 37%, hydrolysis of p-nitrophenyl-beta-2-acetamido-2-deoxy-D-galactopyranoside to 34%
Urea
-
19%, 33% and 40% inhibition with 4, 6 and 8 M
Urea
44% inhibition at 1 mM
Zn2+
-
100 mM
Zn2+
-
2 mM cause 57% inhibition, 10 mM cause 78% inhibition
Zn2+
-
with 0.03 mM 88.6% of activity remains
Zn2+
-
1 mM, 86% inhibition of isoenzyme I, 62% inhibition of isoenzyme II
Zn2+
-
0.5 mM, significant inhibition
Zn2+
-
minor isozyme: 8% of activity remains with 5 mM, major isozyme: 40% of activity remains with 2 mM
Zn2+
42% inhibition at 1 mM, 87% at 50 mM
Zn2+
about 85% residual activity at 1 mM
Zn2+
-
all 4 isozymes, at 10 mM inhibition ranges from 20% for beta-NAHA-IC to 45% for beta-NAHA-II
Zn2+
-
isoenzyme I; isoenzyme II
Zn2+
56% residual activity at 1 mM
Zn2+
-
30%, 58% and 73% inhibition with 0.01 mM, 2 mM and 10 mM
Zn2+
-
concentration of 1 mM causes 70-80% inhibition
additional information
-
the addition of H2O2, 2-mercaptoethanol, urea, Triton X-100, N-ethylmaleimide or 2-iodoacetamide has no or little effect on the activities of the enzymes
-
additional information
-
high substrate concentrations, i.e. concentrations above 0.2 mM
-
additional information
no inhibition by 1-deoxynojirimycin and 1,4-deoxy-1,4-imino-D-arabinitol; no inhibition by 2-acetamide-1,2-deoxynojirymycin, 1-deoxynojirimycin, and 1,4-deoxy-1,4-imino-D-arabinitol
-
additional information
no inhibition by 1-deoxynojirimycin and 1,4-deoxy-1,4-imino-D-arabinitol; no inhibition by 2-acetamide-1,2-deoxynojirymycin, 1-deoxynojirimycin, and 1,4-deoxy-1,4-imino-D-arabinitol
-
additional information
-
no inhibition by 1-deoxynojirimycin and 1,4-deoxy-1,4-imino-D-arabinitol; no inhibition by 2-acetamide-1,2-deoxynojirymycin, 1-deoxynojirimycin, and 1,4-deoxy-1,4-imino-D-arabinitol
-
additional information
-
design and synthesis of acetamido tri- and tetra-hydroxyazepanes as potent and selective beta-N-acetylhexosaminidase inhibitors
-
additional information
-
design and synthesis of acetamido tri- and tetra-hydroxyazepanes as potent and selective beta-N-acetylhexosaminidase inhibitors
-
additional information
-
not inhibitory: EDTA
-
additional information
-
total HEX activity decreases by the 21st day of lactation in comparison to the 3rd day after postpartum. Total HEX activity significantly decreases by the 100th day of lactation, as compared to milk taken on the 3rd day of lactation. Activity of HEX A significantly decreases by the 21st and 100th day of lactation as compared to the 3rd day of lactation. The activity of HEX B significantly decreases on the 21st day of lactation as compared to activity in milk obtained on the 3rd day, and tends to decrease at the 100th day of lactation in comparison to the 3rd day
-
additional information
-
streptozotocin does not appear to act as an irreversible inhibitor
-
additional information
-
synthesis and development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors, inhibitor enzyme interactions and binding structures, overview
-
additional information
low inhibition with 2-acetamido-1,2-dideoxynojirimycin, streptozotocin, N-acetylglucosamine and N-acetylgalactosamine
-
additional information
-
low inhibition with 2-acetamido-1,2-dideoxynojirimycin, streptozotocin, N-acetylglucosamine and N-acetylgalactosamine
-
additional information
not inhibited by aprotinin and trypsin
-
additional information
-
not inhibited by (Z)-3-methyl-2-(((E)-naphthalen-1-ylmethylene) hydrazono)thiazolidin-4-one
-
additional information
not inhibited by EDTA, 2-mercaptoethanol, imidazole, iodoacetamide, or Triton X-100
-
additional information
-
not inhibited by EDTA, 2-mercaptoethanol, imidazole, iodoacetamide, or Triton X-100
-
additional information
-
-
-
additional information
-
not: N-acetyl-D-galactosamine
-
additional information
-
-
additional information
-
-
-